Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021.  https://doi.org/10.3322/caac.21660.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. https://doi.org/10.3322/caac.21332.

Article  PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Article  PubMed  Google Scholar 

Atallah GA, Aziz Abd NH, Teik CK, Shafiee MN, Kampan NC. New Predictive Biomarkers for Ovarian Cancer. Diagnostics (Basel). 2021;11(3):465. https://doi.org/10.3390/diagnostics11030465.

Article  CAS  PubMed  Google Scholar 

Krzystyniak J, Ceppi L, Dizon DS, Birrer MJ. Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer. Ann Oncol. 2016;27(Suppl 1):i4–10. https://doi.org/10.1093/annonc/mdw083.

Article  PubMed  PubMed Central  Google Scholar 

Lee YJ, Kim HS, Rim JH, Lee JY, Nam EJ, Kim SW, et al. Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer. BMC Cancer. 2020;20(1):185. https://doi.org/10.1186/s12885-020-6688-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palaia I, Tomao F, Sassu CM, Musacchio L, Benedetti PP. Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches. Onco Targets Ther. 2020;13:6109–29. https://doi.org/10.2147/OTT.S205950.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376–88. https://doi.org/10.1016/S0140-6736(13)62146-7.

Article  PubMed  Google Scholar 

Prat J. Pathology of borderline and invasive cancers. Best Pract Res Clin Obstet Gynaecol. 2017;41:15–30. https://doi.org/10.1016/j.bpobgyn.2016.08.007.

Article  PubMed  Google Scholar 

Arneth B. Tumor Microenvironment. Medicina (Kaunas). 2019;56(1):15. https://doi.org/10.3390/medicina56010015.

Article  PubMed  Google Scholar 

Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 2012;72(1):66–75. https://doi.org/10.1158/0008-5472.CAN-11-2178.

Article  CAS  PubMed  Google Scholar 

Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149–63. https://doi.org/10.2217/fon.09.136.

Article  CAS  PubMed  Google Scholar 

Glare P. Clinical predictors of survival in advanced cancer. J Support Oncol. 2005;3(5):331–9.

PubMed  Google Scholar 

Hedrick CC, Malanchi I. Neutrophils in cancer: heterogeneous and multifaceted. Nat Rev Immunol. 2022;22(3):173–87. https://doi.org/10.1038/s41577-021-00571-6.

Article  CAS  PubMed  Google Scholar 

Olingy CE, Dinh HQ, Hedrick CC. Monocyte heterogeneity and functions in cancer. J Leukoc Biol. 2019;106(2):309–22. https://doi.org/10.1002/JLB.4RI0818-311R.

Article  CAS  PubMed  Google Scholar 

Cedervall J, Hamidi A, Olsson AK. Platelets, NETs and cancer. Thromb Res. 2018;164(Suppl 1):S148–52. https://doi.org/10.1016/j.thromres.2018.01.049.

Article  CAS  PubMed  Google Scholar 

Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493-503. https://doi.org/10.1016/S1470-2045(14)70263-3.

Article  PubMed  Google Scholar 

Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366(7):610–8. https://doi.org/10.1056/NEJMoa1110352.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang H, Liu Q, Zhu L, Zhang Y, Lu X, Wu Y, et al. Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Patients with Cervical Cancer. Sci Rep. 2019;9(1):3284. https://doi.org/10.1038/s41598-019-39150-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stoiber D, Assinger A. Platelet-Leukocyte Interplay in Cancer Development and Progression. Cells. 2020;9(4):855. https://doi.org/10.3390/cells9040855.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kodama J, Miyagi Y, Seki N, Tokumo K, Yoshinouchi M, Kobashi Y, et al. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 1999;82(1):107–10. https://doi.org/10.1016/s0301-2115(98)00227-9.

Article  CAS  PubMed  Google Scholar 

Lee SH, Lee JG, Choi YJ, Seol YM, Kim H, Kim YJ, et al. Prognosis palliative care study, palliative prognostic index, palliative prognostic score and objective prognostic score in advanced cancer: a prospective comparison. BMJ Support Palliat Care. 2021. https://doi.org/10.1136/bmjspcare-2021-003077.

Article  PubMed  Google Scholar 

Yoshida A, Sarian LO, Marangoni MJ, Firmano IC, Derchain SF. Diagnostic Value of the Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Thrombocytosis in the Preoperative Investigation of Ovarian Masses. Rev Bras Ginecol Obstet. 2020;42(7):397–403. https://doi.org/10.1055/s-0040-1712991.

Article  PubMed  Google Scholar 

Cramer DW, Benjamin Iv WJ, Vitonis AF, Berkowitz R, Goodman A, Matulonis U. Differential blood count as triage tool in evaluation of pelvic masses. Int J Gynecol Cancer. 2021;31(5):733–43. https://doi.org/10.1136/ijgc-2019-001103.

Article  PubMed  Google Scholar 

Huang CY, Yang YC, Wang KL, Chen TC, Chen JR, Weng CS, et al. Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer. Taiwan J Obstet Gynecol. 2016;55(3):405–9. https://doi.org/10.1016/j.tjog.2016.04.017.

Article  PubMed  Google Scholar 

Seckin KD, Karslı MF, Yucel B, Bestel M, Yıldırım D, Canaz E, et al. The utility of tumor markers and neutrophil lymphocyte ratio in patients with an intraoperative diagnosis of mucinous borderline ovarian tumor. Eur J Obstet Gynecol Reprod Biol. 2016;196:60–3. https://doi.org/10.1016/j.ejogrb.2015.10.025.

Article  CAS  PubMed  Google Scholar 

Kim HS, Choi HY, Lee M, Suh DH, Kim K, No JH, et al. Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study. Cancer Res Treat. 2016;48(1):250–8. https://doi.org/10.4143/crt.2014.324.

Article  CAS  PubMed  Google Scholar 

Abu-Shawer O, Abu-Shawer M, Hirmas N, Alhouri A, Massad A, Alsibai B, et al. Hematologic markers of distant metastases and poor prognosis in gynecological cancers. BMC Cancer. 2019;19(1):141. https://doi.org/10.1186/s12885-019-5326-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kokcu A, Kurtoglu E, Celik H, Tosun M, Malatyalioglu E, Ozdemir AZ. May the platelet to lymphocyte ratio be a prognostic factor for epithelial ovarian cancer? Asian Pac J Cancer Prev. 2014;15(22):9781–4. https://doi.org/10.7314/apjcp.2014.15.22.9781.

Article  PubMed  Google Scholar 

Polat M, Senol T, Ozkaya E, Ogurlu Pakay G, Cikman MS, Konukcu B, et al. Neutrophil to lymphocyte and platelet to lymphocyte ratios increase in ovarian tumors in the presence of frank stromal invasion. Clin Transl Oncol. 2016;18(5):457–63. https://doi.org/10.1007/s12094-015-1387-7.

Article  CAS  PubMed  Google Scholar 

Meerwaldt JH, Haije WG, Cooper EH, Pidcock NB, Burg ME v d. Biochemical aids in the monitoring of patients with ovarian cancer. Gynecol Oncol. 1983;16(2):209–18. https://doi.org/10.1016/0090-8258(83)90095-1.

Article  CAS  PubMed  Google Scholar 

Medina Fernández FJ, Muñoz-Casares FC, Arjona-Sánchez A, Casado-Adam A, Gómez-Luque I, Garcilazo Arismendi DJ, et al. Postoperative time course and utility of inflammatory markers in patients with ovarian peritoneal carcinomatosis treated with neoadjuvant chemotherapy, cytoreductive surgery, and HIPEC. Ann Surg Oncol. 2015;22(4):1332–40. https://doi.org/10.1245/s10434-014-4096-5.

Article  PubMed  Google Scholar 

Badora-Rybicka A, Nowara E, Starzyczny-Slota D. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer. ESMO Open. 2016;1(2):e000039.

Article  PubMed  PubMed Central  Google Scholar 

Li Z, Hong N, Robertson M, Wang C, Jiang G. Preoperative red cell distribution width and neutrophil-to-lymphocyte ratio predict survival in patients with epithelial ovarian cancer. Sci Rep. 2017;7:43001. https://doi.org/10.1038/srep43001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Y, Chen S, Zheng C, Ding M, Zhang L, Wang L, et al. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer. BMC Cancer. 2017;17(1):285. https://doi.org/10.1186/s12885-017-3220-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoshida K, Yoshikawa N, Shirakawa A, Niimi K, Suzuki S, Kajiyama H, et al. Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma. J Gynecol Oncol. 2019;30(6):e85.

Article  PubMed